Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a “buy” rating and a $50.00 price target on the stock. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Finally, Guggenheim boosted their price target on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Up 2.1%

Damora Therapeutics, Inc. Common Stock stock opened at $20.65 on Friday. The stock has a 50-day simple moving average of $27.42 and a 200 day simple moving average of $26.07. Damora Therapeutics, Inc. Common Stock has a 12-month low of $3.64 and a 12-month high of $38.33. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -6.13 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. As a group, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Insider Buying and Selling

In other news, CEO Jennifer Jarrett bought 12,500 shares of the stock in a transaction on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $260,000. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $303,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $7,398,000. Finally, Braidwell LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $42,146,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.